Stock AZTA AZENTA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Azenta, Inc.

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
52.09 USD -0.86% Intraday chart for Azenta, Inc. +1.80% -20.03%
Apr. 08 Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Apr. 04 Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating MT

Business Summary

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Number of employees: 3,500

Sales per Business

USD in Million2022Weight2023Weight Delta
Life Sciences Services
54.1 %
356 64.1 % 360 54.1 % +1.02%
Life Sciences Products
45.9 %
199 35.9 % 305 45.9 % +53.18%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
53.4 %
371 66.7 % 355 53.4 % -4.18%
Rest of Europe
16.5 %
-- 110 16.5 % -
Africa
9.8 %
-- 65 9.8 % -
Asia/Pacific/Other
7.8 %
29 5.2 % 52 7.8 % +80.04%
China
7.8 %
48 8.7 % 52 7.8 % +7.68%
United Kingdom
4.0 %
-- 27 4.0 % -
North America
0.6 %
3 0.5 % 4 0.6 % +43.37%

Managers

Managers TitleAgeSince
Stephen Schwartz CEO
 Chief Executive Officer 65 10-04-04
Herman Cueto DFI
 Director of Finance/CFO 50 23-10-15
Michael Paulo CTO
 Chief Tech/Sci/R&D Officer - 17-06-30
Robin Vacha COO
 Chief Operating Officer - 13-12-31
Sara Silverman IRC
 Investor Relations Contact - 20-12-31
Olga Pirogova HRO
 Human Resources Officer - 23-07-31
Violetta Hughes AUD
 Comptroller/Controller/Auditor - 22-12-31
Rob Woodward LAW
 General Counsel - 09-10-31
Claribel Purcell SAM
 Sales & Marketing - 22-10-31
John O'Brien PRN
 Corporate Officer/Principal 53 10-04-30

Members of the board

Members of the board TitleAgeSince
Martin Madaus BRD
 Director/Board Member 64 Jan. 29
Edward Bousa BRD
 Director/Board Member 65 Jan. 29
Stephen Schwartz CEO
 Chief Executive Officer 65 10-04-04
Didier Hirsch BRD
 Director/Board Member 72 Jan. 29
Michael Rosenblatt BRD
 Director/Board Member 76 18-09-04
Robyn Davis BRD
 Director/Board Member 63 13-06-27
Tina Nova BRD
 Director/Board Member 70 23-01-30
Erica McLaughlin BRD
 Director/Board Member 48 20-04-02
Frank Casal BRD
 Director/Board Member 70 21-11-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 69,227,004 54,707,981 ( 79.03 %) 13,461,869 ( 19.45 %) 79.03 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.13 %
5,650,051 10.13 % 341 M $
BlackRock Advisors LLC
9.421 %
5,253,597 9.421 % 317 M $
Kayne Anderson Rudnick Investment Management LLC
8.291 %
4,623,310 8.291 % 279 M $
Politan Capital Management LP
8.209 %
4,578,003 8.209 % 276 M $
Dimensional Fund Advisors LP
4.002 %
2,231,792 4.002 % 135 M $
Norges Bank (13F)
3.878 %
2,162,356 3.878 % 130 M $
BNY Mellon Investment Adviser, Inc.
3.736 %
2,083,555 3.736 % 126 M $
STATE STREET CORPORATION
3.195 %
1,781,479 3.195 % 107 M $
Conestoga Capital Advisors LLC
2.316 %
1,291,284 2.316 % 78 M $
RBC Global Asset Management (US), Inc.
2.034 %
1,134,156 2.034 % 68 M $

Company contact information

Azenta, Inc.

200 Summit Drive 6th floor

01803, Burlington

+978 262 2626

http://www.azenta.com
address Azenta, Inc.(AZTA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Azenta, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
52.09 USD
Average target price
66.8 USD
Spread / Average Target
+28.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AZENTA, INC. Stock Azenta, Inc.
-20.03% 2.9B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.84B
LONZA GROUP AG Stock Lonza Group AG
+46.28% 41.25B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.68B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.18B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZTA Stock
  4. Company Azenta, Inc.